MedPath

Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer

Phase 2
Completed
Conditions
Pancreatic Cancer
Interventions
Registration Number
NCT00161213
Lead Sponsor
University of Medicine and Dentistry of New Jersey
Brief Summary

RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gemcitabine together with imatinib mesylate may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving gemcitabine together with imatinib mesylate works as first-line therapy in treating patients with locally advanced or metastatic pancreatic cancer.

Detailed Description

OBJECTIVES:

Primary

* Evaluate the time to progression in patients with locally advanced or metastatic pancreatic cancer treated with gemcitabine hydrochloride and imatinib mesylate as first-line therapy.

Secondary

* Assess the response rate in patients treated with this regimen.

* Assess the percentage of patients treated with this regimen who survive 1 year or more.

* Assess the toxicity of this regimen in these patients.

* Assess the overall survival of patients treated with this regimen.

OUTLINE: This is a multicenter, nonrandomized, open-label, uncontrolled study.

Patients receive gemcitabine hydrochloride IV over 120 minutes on days 3 and 10 and oral imatinib mesylate on days 1-5 and 8-12. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 42 patients will be accrued for this study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
44
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Gemcitabine and Imatinibgemcitabine hydrochloride-
Gemcitabine and Imatinibimatinib mesylate-
Primary Outcome Measures
NameTimeMethod
Progression-free Survival4 years

Progression-free survival in months. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

Secondary Outcome Measures
NameTimeMethod
1-year Survival Rate5 years

Percentage of subjects who survive up to 1 year

Response Rate5 years

Response rate as defined by a best response of "Stable Disease or better."

Overall Survival5 years

Trial Locations

Locations (8)

Robert H. Lurie Comprehensive Cancer Center at Northwestern University

🇺🇸

Chicago, Illinois, United States

CentraState Medical Center

🇺🇸

Freehold, New Jersey, United States

Cancer Institute of New Jersey at Hamilton

🇺🇸

Hamilton, New Jersey, United States

Jersey Shore Cancer Center at Jersey Shore University Medical Center

🇺🇸

Neptune, New Jersey, United States

Central Jersey Oncology Group

🇺🇸

New Brunswick, New Jersey, United States

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School

🇺🇸

New Brunswick, New Jersey, United States

Saint Peter's University Hospital

🇺🇸

New Brunswick, New Jersey, United States

New Jersey Medical School

🇺🇸

Newark, New Jersey, United States

Robert H. Lurie Comprehensive Cancer Center at Northwestern University
🇺🇸Chicago, Illinois, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.